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Introduction
Imidazolines, also known as dihydroimidazoles, are a class of heterocyclic
compounds belonging to the imidazole family. Imidazoles when reduced by hydrogen
in the presence of a catalyst become one source of the production of imidazolines
and imidazolidines. Imidazolines are the products of partial hydrogenation (partial
reduction of imidazole). Imidazolidines are the product of complete hydrogenation (full
reduction of imidazole). Partial reduction of imidazole gives rise to three imidazoline
constitutional isomers, 2-imidazolines, 3-imidazolines, and 4-imidazolines. Of these
three constitutional isomers, the most commonly observed and extensively
researched isomer is 2-imidazoline.
Imidazolines are versatile heterocycle compounds whose industrial applications as
surfactants and anti-corrosion agent, catalysis and ligand potential, as well as
pharmacophore abilities have motivated researchers towards developing continuous
methods for accessing them. Imidazolines have been experimentally proven to act as
proteasome inhibitors, causing the apoptosis in cell systems that are dependent on
proteasomal function for cellular viability.
Proteasome Inhibition
The proteasome is a protease responsible for maintaining cell viability, homeostasis
and regulation of cellular functions. The human proteasome, commonly referred to as
the h26S, is comprised of the catalytic 20S core particle and two 19S regulatory caps.
When these three groups assemble the 26S proteasome is formed and its function is
to cleave proteins marked for degradation into their resulting amino acids. These
amino acids can then be recycled by the cell towards other necessary cellular
functions. The 19S caps act as recognition sites, identifying proteins that have been
polyubiquitinated and funneling them into the catalytic 20S particle for degradation.
Developing molecules that specifically target the proteasome result in modulation of
proteasome activity when they bind. This modulation changes the rate of peptide
degradation done by the proteasome. Imidazolines scaffolds have been
experimentally shown to decrease proteasome activity. This decrease effects the
degree to with the proteasome can effectively degrade proteins to maintain
intercellular processes. Polyubiquitinated proteins begin to accumulate in the cell and
result in downstream apoptosis.
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Background on the Synthesis of Imidazolines
Heine-Type Ring Expansion Amide Dehydration Reactions
Condensation of Nitriles Under Lewis Acid Catalysis Munchnone [3+2] Cycloaddition Reaction
Current Literature on Imidazoline and Aziridine Synthesis
Accessing 2-Imidazolines by Ring Expansion of Imidoylaziridines Accessing of Chiral Aziridines by Pyrrolidine Enamine-Iminium Cascade
Hypothesis
Diversified 2-Imidazoline scaffolds can be accessed through a tandem enamine-iminium catalyzed Michael addition of O-functionalized N-
Hydroxyamidines, in four steps from commercially available starting material, to produce a small library of compounds for biological evaluation.
Experimental Results
Step 1: Amide formation by Schotten Baumann Reaction Step Two: Synthesis of the N-Hydroxyamidine
Understanding Multiple Myeloma
Multiple myeloma is a malignant cancer of the plasma cells, found in blood. Although
largely incurable, the lifespan of patients can be prolonged through the use of drug
therapy. The target of synthetic drugs and polypeptide therapies is the proteasome,
which has been identified as the linchpin for activating cell death. Bortezomib, is the
one of leading proteasome inhibitors, and has been approved in the U.S. for the
treatment of multiple myeloma. Drugs like Bortezomib, exhibit activity though
competitive inhibition of the proteasome. This causes proteolysis to stop, thereby
causing the accumulation of redundant and damaged proteins in the cell which result
in cell death. This ability directly translates to the molecules’ potent anticancer activity.
However over time random mutations occur in cancer cells proteasomes that result
loss of efficacy for Bortezomib and similar therapies. Apart from loss of activity,
extended use of Bortezomib has resulted in severe off-target effects, due to lack of
specificity for the proteasome of cancerous cells. In response to this, research has
begun to investigate other methods of proteasome inhibition in an effort to combat the
growing resistance to current competitive inhibitors like Bortezomib.
Understanding Tuberculosis
Tuberculosis is an infectious disease that is spread by mycobacterium tuberculosis
(mTB). The emergence of multidrug and extensive drug resistant forms of TB have
revitalized the need for novel scaffolds for TB inhibition. Often miseducation about TB
and its behavior result in patients abruptly stopping treatments like Isoniazids as soon
as visible symptoms disappear, instead of continuing the drug regiment in its entirety.
The normal treatment time for a TB infection is 6-8 months to insure there is no
secondary infection. One of the key factors that is being targeted in an attempt to
combat TB is the inhibition of the proteasome. When mTB switches from its active
mode to its passive or persistent mode, it is forced to use different metabolic
pathways to survive in a low nutrient environment. One of the key factors to that
survival is the recycling of proteins to make the amino acids available for other
cellular operations, which the proteasome is responsible for.
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